During the meeting, on the afternoon of June 27th, general manager li shugang was invited to attend the pharmaceutical enterprise symposium held by tianjin government, and also invited by roche, Johnson & Johnson, novartis, tianjin tianshili, beimin university, China biotechnology group and other large pharmaceutical companies. Vice mayor of tianjin, director of tianjin science and technology commission, director of teda administrative committee and so on attended the symposium. They reaffirmed tianjin's preferential policies to the biopharmaceutical industry in the form of official, and expressed that they would promote the development of tianjin's biopharmaceutical industry in various flexible forms with the largest preferential policy in the country. The symposium also asked invited enterprises to give Suggestions and Suggestions for the development of tianjin biopharmaceutical industry. Mr. Li submitted a proposal report on the development mode of tianjin biopharmaceutical industry, talents and key technology introduction, which was recognized by participants.

During the meeting, Mr. Li also accepted an exclusive interview with zhang hong, reporter of the northern economic times. According to the theme of this conference, Mr. Li said that we must seize the opportunity of the world biotechnology revolution and industrial revolution, and cultivate the biological industry to become the pillar industry of China's high-tech field. In the biotechnology industry economy, the output value of biomedicine industry accounts for more than 70%, and the state's support to the biomedicine industry is also put in the first place. For domestic pharmaceutical enterprises, we must seize this opportunity to complete the industrial restructuring with this strong wind. We will shift to bio-pharmaceutical industries with high technology content, low energy consumption and high added value, and create new economic growth points to cope with a possible new round of economic recession. For the high-tech biopharmaceutical industry like korun, if you master the technology, you will master the core. When you have a good project, you have the initiative. Research and development projects with market prospects, become the survival of such a high-tech r & d companies. For the biopharmaceutical industry, the general trend is that the market and capital reserves have become mature and perfect, but the lack of core technologies and projects.